M-254

N/A

Report date: 2023/02/18 19:47:14

Base Information

Drug NameM-254
Drug Alias NamesFcDC-SIGN-targeted sialylated recombinant IgG Fc fragmenttetra-Fc–sialylated IVIgs4-IVIghsIVIG +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMomenta
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMomenta Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPurpura, Thrombocytopenic, Idiopathic

Other Information

ATC CodeN/A
Related LinksN/A